IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
1.270
-0.060 (-4.51%)
At close: May 30, 2025, 4:00 PM
1.222
-0.048 (-3.80%)
After-hours: May 30, 2025, 7:59 PM EDT
IGM Biosciences Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for IGM Biosciences stock ranges from a low of $1.50 to a high of $22. The average analyst price target of $6.14 forecasts a 383.46% increase in the stock price over the next year.
Price Target: $6.14 (+383.46%)
Analyst Consensus: Hold
* Price targets were last updated on Jan 10, 2025.
Analyst Ratings
The average analyst rating for IGM Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 7 | 7 | 7 | 7 | 7 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Jan 13, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $48 → $2 | Strong Buy → Hold | Downgrades | $48 → $2 | +57.48% | Jan 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $12 → $2 | Hold | Maintains | $12 → $2 | +57.48% | Jan 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $27 → $2.5 | Strong Buy → Hold | Downgrades | $27 → $2.5 | +96.85% | Jan 10, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $20 → $1.5 | Buy → Hold | Downgrades | $20 → $1.5 | +18.11% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
6.01M
from 2.68M
Increased by 124.45%
Revenue Next Year
8.72M
from 6.01M
Increased by 45.07%
EPS This Year
-1.08
from -3.24
EPS Next Year
-0.62
from -1.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.2M | 25.2M | 25.2M | ||
| Avg | 6.0M | 8.7M | 11.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 841.4% | 319.4% | 189.1% | ||
| Avg | 124.4% | 45.1% | 29.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.09 | -0.06 | -0.04 | ||
| Avg | -1.08 | -0.62 | -0.76 | ||
| Low | -1.98 | -2.24 | -2.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.